0000000000291372

AUTHOR

Euy Sung Moon

0000-0003-0447-1355

showing 11 related works from this author

Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems

2021

Abstract 44Sc is an increasingly investigated positron emitter for use in positron emission tomography (PET) imaging. However, 44Sc is a non-pure positron emitter, since prompt photons are co-emitted during the decay process. This study investigates coincidence energy spectra of 44Sc and its impact on PET quantification on a preclinical and clinical PET system in comparison with 18F. The raw data of the coincidence events revealed characteristic differences comparing the photon energy distribution of 44Sc and 18F. Due to prompt gamma emission of 44Sc, activity recovery is underestimated on PET systems. However, clinical PET imaging of 44Sc with acceptable quantitative accuracy appears feasi…

RadiationMaterials sciencemedicine.diagnostic_testAstrophysics::High Energy Astrophysical PhenomenaPhysics::Medical PhysicsPositron emittersGamma rayPet imagingPhoton energy010403 inorganic & nuclear chemistry01 natural sciencesQuantitative accuracyCoincidence030218 nuclear medicine & medical imaging0104 chemical sciences03 medical and health sciences0302 clinical medicineNuclear magnetic resonancePositron emission tomographymedicinePhysics::Accelerator PhysicsPet quantificationApplied Radiation and Isotopes
researchProduct

Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot …

2021

Background: This exploratory study was to assess clinical and safety data with a novel fibroblast activation protein inhibitor-based targeted theranostics as a salvage treatment option in radioiodi...

AdultMaleEndocrinology Diabetes and MetabolismSalvage treatmentIndiaPilot ProjectsEndocrinologyFibroblast activation protein alphaRefractoryPositron Emission Tomography Computed TomographyMedicineHumansProspective StudiesThyroid NeoplasmsPrecision MedicineThyroid cancerProtein Kinase InhibitorsAgedbusiness.industryPhenylurea CompoundsMiddle AgedSorafenibmedicine.diseaseCancer researchQuinolinesFemalebusinessThyroid : official journal of the American Thyroid Association
researchProduct

AAZTA5-BN as a Versatile Probe for Radiometal Labelling, Nuclear Imaging and Radionuclide Therapy of Gastrin Releasing Peptide Positive Tumors

2021

Nuclear imagingChemistryGastrin-releasing peptideLabellingRadionuclide therapyCancer research59. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin
researchProduct

[68Ga]Ga-DATA5m.SA.FAPi PET/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor Imaging.

2020

Computer. AutomationPET-CTPathologymedicine.medical_specialtyLiver tumorbusiness.industryLiver NeoplasmsFocal nodular hyperplasiaGallium RadioisotopesGeneral Medicinemedicine.diseaseFocal Nodular HyperplasiaPositron Emission Tomography Computed TomographyTracer uptakeMedicineHumansRadiology Nuclear Medicine and imagingbusinessNuklearmedizin. Nuclear medicine
researchProduct

Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours

2021

Abstract Aim Gallium-68-labelled inhibitors of the fibroblast activation protein (FAPi) enable positron emission tomography/computed tomography (PET/CT) imaging of fibroblast activation. We evaluated if [68Ga]Ga-DATA5m.SA.FAPi PET/CT is related to Ki-67 as a marker of tumour aggressiveness in patients with liver metastases of NET. Methods Thirteen patients with liver metastases of a histologically confirmed NET who underwent PET/CT with [68Ga]Ga-DATA5m.SA.FAPi, [18F]FDG and [68Ga]Ga-DOTA-TOC were retrospectively analyzed. PET-positive liver tumour volumes were segmented for calculation of volume, SUVmax and PET-positive tumour fraction (TF). PET parameters were correlated with Ki-67. Result…

Pathologymedicine.medical_specialtyProliferation index030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFibroblast activation protein alphaPositron Emission Tomography Computed TomographymedicineHumansRadiology Nuclear Medicine and imagingIn patientFibroblastGrading (tumors)Retrospective StudiesPET-CTbiologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsGeneral MedicineFibroblastsNeuroendocrine TumorsKi-67 Antigenmedicine.anatomical_structurePositron emission tomography030220 oncology & carcinogenesisKi-67biology.proteinbusinessNuklearmedizin - NuclearMedicine
researchProduct

Development of FAP-inhibitors based on squaric acid linked DOTA and DATA5m chelators

2020

chemistry.chemical_compoundchemistryDOTASquaric acidCombinatorial chemistry58. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin
researchProduct

Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy.

2021

Targeting vectors bound to a chelator represent a significant fraction of radiopharmaceuticals used nowadays for diagnostic and therapeutic purposes in nuclear medicine. The use of squaramides as coupling units for chelator and targeting vector helps to circumvent the disadvantages of several common coupling methods. This review gives an overview of the use of squaric acid diesters (SADE) as linking agents. It focuses on the conjugation of cyclic chelators, e.g., DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), as well as hybrid chelators like AAZTA5 (6-pentanoic acid-6-amino-1,4-diazepine tetracetic acid) or DATA5m (6-pentanoic acid-6-amino-1,4-diazapine-triacetate) to diff…

medicine.drug_classBiomedical EngineeringPharmaceutical ScienceBioengineering02 engineering and technologySquaric acidMonoclonal antibody01 natural scienceschemistry.chemical_compoundFibroblast activation protein alphaIn vivoNeoplasmsmedicineDOTAHumansChelationPharmacology010405 organic chemistryChemistryOrganic Chemistry021001 nanoscience & nanotechnologyCombinatorial chemistrySmall molecule0104 chemical sciencesPositron-Emission TomographyRadiopharmaceuticals0210 nano-technologyCyclobutanesBiotechnologyConjugateBioconjugate chemistry
researchProduct

AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A″-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild …

2021

Abstract Background Combining the advantages of both cyclic and acyclic chelator systems, AAZTA (1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-methylperhydro-1,4-diazepine) is well suited for complexation of various diagnostic and therapeutic radiometals such as gallium-68, scandium-44 and lutetium-177 under mild conditions. Due to its specificity for primary amines and pH dependent binding properties, squaric acid (SA) represents an excellent tool for selective coupling of the appropriate chelator to different target vectors. Therefore, the aim of this study was to evaluate radiolabeling properties of the novel bifunctional AAZTA5-SA being coupled to a model antibody (bevacizumab) i…

Cancer Researchmedicine.drug_classRadiochemistryKineticsSize-exclusion chromatographySquaramideSquaric acidMonoclonal antibody030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesismedicineMolecular MedicineDOTARadiology Nuclear Medicine and imagingChelationBifunctionalNuclear Medicine and Biology
researchProduct

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

2020

Abstract Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid containing bifunctional DATA5m and DOTA chelators relied on UAMC…

Computer. Automationlcsh:Medical physics. Medical radiology. Nuclear medicine540 Chemistry and allied sciencesPREPPharmacology. Therapylcsh:R895-920Gallium-68lcsh:RM1-950610 MedizinFAPDATA5mChemistrylcsh:Therapeutics. PharmacologyDOTA540 Chemie610 Medical sciencesSquaric acidneoplasmsEJNMMI Radiopharmacy and Chemistry
researchProduct

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi

2021

Recently, the first squaramide-(SA) containing FAP inhibitor-derived radiotracers were introduced. DATA5m.SA.FAPi and DOTA.SA.FAPi with their non-radioactive complexes showed high affinity and selectivity for FAP. After a successful preclinical study with [68Ga]Ga-DOTA.SA.FAPi, the first patient studies were realized for both compounds. Here, we present a new squaramide-containing compound targeting FAP, based on the AAZTA5 chelator 1,4-bis-(carboxylmethyl)-6-[bis-(carboxymethyl)-amino-6-pentanoic-acid]-perhydro-1,4-diazepine. For this molecule (AAZTA5.SA.FAPi), complexation with radionuclides such as gallium-68, scandium-44, and lutetium-177 was investigated, and the in vitro properties of…

PREPPharmaceutical ScienceAcetatesLutetiumLigands030218 nuclear medicine & medical imagingAnalytical ChemistrySerinechemistry.chemical_compoundQD241-4410302 clinical medicineFibroblast activation protein alphaPositron Emission Tomography Computed TomographyDrug Discoverylutetium-177AAZTA; scandium-44; lutetium-177; FAP; SA; DPP; PREPQuinineChemistrySerine EndopeptidasesAzepinesscandium-44ChemistryChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineSelectivityDPPGallium RadioisotopesConjugated systemArticleHeterocyclic Compounds 1-Ring03 medical and health sciencesSAEndopeptidasesHumansDOTAChelationPhysical and Theoretical ChemistryBiologyAAZTARadioisotopesOrganic ChemistrySquaramideMembrane ProteinsFAPFibroblastsCombinatorial chemistryIn vitroRadiopharmaceuticalsScandiumMolecules
researchProduct

New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress.

2021

Over the past decade, the tumor microenvironment (TME) has become a new paradigm of cancer diagnosis and therapy due to its unique biological features, mainly the interconnection between cancer and stromal cells. Within the TME, cancer-associated fibroblasts (CAFs) demonstrate as one of the most critical stromal cells that regulate tumor cell growth, progression, immunosuppression, and metastasis. CAFs are identified by various biomarkers that are expressed on their surfaces, such as fibroblast activation protein (FAP), which could be utilized as a useful target for diagnostic imaging and treatment. One of the advantages of targeting FAP-expressing CAFs is the absence of FAP expression in q…

fibroblast activation proteincongenital hereditary and neonatal diseases and abnormalitiesStromal cellmedicine.medical_treatmentcancer-associated fibroblastPharmaceutical Science610 Medicine & healthCancer imagingReviewfibroblast activation protein inhibitorMetastasisPharmacy and materia medicaFibroblast activation protein alphaDrug Discoverymedicinetumor microenvironment610 Medicine & healthneoplasmsradiotherapynuclear imagingTumor microenvironmentbusiness.industryRCancerImmunosuppressionmedicine.diseasedigestive system diseasesRadiation therapyRS1-441Cancer researchMolecular MedicineMedicinebusiness
researchProduct